---
title: "Cocrystal Pharma | 10-Q: FY2026 Q1 Revenue: USD 225 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286565996.md"
datetime: "2026-05-15T12:32:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286565996.md)
  - [en](https://longbridge.com/en/news/286565996.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286565996.md)
---

# Cocrystal Pharma | 10-Q: FY2026 Q1 Revenue: USD 225 K

Revenue: As of FY2026 Q1, the actual value is USD 225 K.

EPS: As of FY2026 Q1, the actual value is USD -0.17, missing the estimate of USD -0.15.

EBIT: As of FY2026 Q1, the actual value is USD -2.378 M.

### Segment Revenue

-   **Grant Income**: Cocrystal Pharma, Inc. reported grant income of $225,000 for the three months ended March 31, 2026, compared to $0 for the same period in 2025, stemming from a $500,000 Small Business Innovation Research (SBIR) Phase I award from the NIH/NIAID.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended March 31, 2026, was - $2,299,000, which is comparable to a net loss of - $2,301,000 for the three months ended March 31, 2025.
-   **Research and Development (R&D) Expenses**: R&D expenses were $1,371,000 for Q1 2026, slightly up from $1,360,000 for Q1 2025.
    -   Specific R&D expenses were $1,042,000 in Q1 2026 versus $1,027,000 in Q1 2025.
-   **General and Administrative (G&A) Expenses**: G&A expenses increased to $1,210,000 for Q1 2026 from $981,000 for Q1 2025, primarily due to higher legal and consultant costs, partially offset by lower salary and wages.
    -   Specific G&A related expenses included salaries and personnel costs of $481,000 in Q1 2026 ($544,000 in Q1 2025), insurance costs of $57,000 in Q1 2026 ($62,000 in Q1 2025), stock-based compensation of $84,000 in Q1 2026 ($82,000 in Q1 2025), and other operating expenses of $917,000 in Q1 2026 ($625,000 in Q1 2025).
-   **Loss from Operations**: The company reported a loss from operations of - $2,356,000 for Q1 2026, compared to - $2,341,000 for Q1 2025.
-   **Other Income**: Total other income was $57,000 for Q1 2026, up from $40,000 for Q1 2025, including interest income of $22,000 (down from $37,000 in Q1 2025) and foreign exchange gain of $35,000 (up from $3,000 in Q1 2025).

### Cash Flow

-   **Net Cash Used in Operating Activities**: Net cash used in operating activities was - $2,340,000 for the three months ended March 31, 2026, an improvement from - $2,939,000 for the same period in 2025, primarily due to a reduction in period expenses related to the Influenza A Phase 2a clinical trial.
-   **Cash and Restricted Cash**: As of March 31, 2026, the company had $4,760,000 in cash and restricted cash, a decrease from $7,100,000 at December 31, 2025.

### Unique Metrics

-   **Stock-based Compensation Expense**: Equity-based compensation expense recorded was $84,000 for Q1 2026 and $82,000 for Q1 2025.
-   **Common Stock Outstanding**: As of March 31, 2026, approximately 13,787,453 shares of common stock were outstanding.

### Future Outlook and Strategy

Cocrystal Pharma, Inc. has incurred net losses and negative operating cash flows since its inception, which raises substantial doubt about its ability to continue as a going concern. The company believes its current cash and restricted cash balance of $4,760,000 as of March 31, 2026, will not be sufficient to fund operations beyond the next 12 months. Management plans to fund future operations through additional private or public equity offerings and arrangements with strategic partners, though there is no assurance of such funding being available on acceptable terms or without significant dilution.

### Related Stocks

- [COCP.US](https://longbridge.com/en/quote/COCP.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md)
- [PRO REIT declares May 2026 cash distribution of $0.0375 per unit](https://longbridge.com/en/news/287207393.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)